Effect of Pilates and Kegel Exercises During Pregnancy

March 5, 2025 updated by: Guner CICEK, Hitit University

Effect of Pilates and Kegel Exercises During Pregnancy on Postpartum Urinary and Fecal Incontinence and Women's Quality of Life

Urinary incontinence and fecal incontinence are common health problems in the postpartum period because of their effect on daily life and are likely to reduce quality of life. It is known that the most effective way to protect from UI during pregnancy and the postpartum period is pelvic floor muscle exercise. This study aimed to investigate the effects of Pilates and Kegel exercises applied during pregnancy on the quality of life of urinary and fecal incontinence in the postpartum period.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In this study; the effects of pilates and kegel exercises on urinary and fecal incontinence of pregnant women in the 1st and 3rd months postpartum are investigated and which of the applied pilates and kegel exercises is more effective on urinary and fecal quality of life.67 pregnant women with a mean age of 27.29±3.27 years participated in the study. Pilates exercise group (PEG, n=24), Kegel exercise group (KEG, n=22), and Control group (CG, n=21) were formed with the purposeful method. PEG exercise programs were applied for 8 weeks, 2 days a week, 40 minutes, and KEG for 8 weeks, 4 days a week, 3 sessions per day. The groups were applied the International Incontinence Questionnaire Short Form, Urinary Incontinence Quality of Life Scale, Wexner Continence Assessment Scale, and Fecal Incontinence Quality of Life Scale at 1st. and 3rd. months postpartum

Study Type

Observational

Enrollment (Actual)

67

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Central
      • Corum, Central, Turkey, 19030
        • Hitit University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Pregnancy women

Description

Inclucision Criteria

  • Being between the ages of 18-38 years,
  • Not having a condition that prevents exercise,
  • Being in the 3rd trimester of pregnancy,
  • Voluntarily accepting to participate in the study, a
  • Answering each of the scale items,
  • Having a vaginal (normal) birth.

Exclusion Criteria:

  • Not being between the ages of 18-38,
  • Having a condition that prevents exercise,
  • Not being in the 1st and 2nd trimesters of pregnancy,
  • Leaving scale items blank, and having a cesarean section.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline Anthropometric Measurements (Weight, Height, BMI)
Time Frame: 2021 june
Baseline meausurement ( 1 week) Participants will be evaluated at baseline. Data collection refers to anthropometric parameters (Weight, height and BMI. BMI BMI will calculated as weight in kilograms divided by height squared (kg/m2) in meters
2021 june
Urinary Incontinence Quality of Life Scale (I-QOL)-Baseline and Follow-up Measurements
Time Frame: June 2021 (Baseline) and 1st and 3rd months postpartum

Urinary Incontinence Quality of Life Scale (I-QOL) - Evaluates the quality of life related to urinary incontinence.

Description: Evaluates the quality of life related to urinary incontinence. This scale was applied at baseline and at the 1st and 3rd months postpartum.

Minimum Value: 0 (Poor quality of life) Maximum Value: 100 (High quality of life) Higher Scores Indicate: Better quality of life Data Aggregation: Mean ± SD and comparison of scores between groups using ANOVA.

June 2021 (Baseline) and 1st and 3rd months postpartum
Effect of an 8-Week Exercise Intervention on Urinary and Fecal Incontinence - Measured by ICIQ-UI Short Form and Wexner Continence Assessment Scale
Time Frame: Baseline (June 2021), Post-intervention (August 2021), and Follow-up at 1st and 3rd months postpartum.

This measure evaluates the effect of an 8-week exercise intervention on urinary and fecal incontinence in pregnant women. Urinary incontinence severity will be assessed using the ICIQ-UI SF, and fecal incontinence using the Wexner Scale at baseline, post-intervention (8 weeks), and 1st and 3rd months postpartum.

Participants are divided into two groups:

Pilates Group (PEG): Performed Pilates twice a week, 40 minutes per session, for 8 weeks, using a mini ball, resistance band, and Pilates ring.

Kegel Group (KEG): Performed Kegel exercises 4 days a week, 3 sessions per day, for 8 weeks, involving controlled pelvic floor contractions and relaxations.

Measurement Tools:

Urinary Incontinence: ICIQ-UI SF Fecal Incontinence: Wexner Scale

Baseline (June 2021), Post-intervention (August 2021), and Follow-up at 1st and 3rd months postpartum.
International Incontinence Questionnaire Short Form Score (ICIQ-SF) - Urinary Incontinence Impact
Time Frame: 2021 September 2021 November
Description: Assesses the impact of urinary incontinence on daily life. Minimum Value: 0 (No impact) Maximum Value: 21 (Severe impact) Higher Scores Indicate: Worse quality of life Data Aggregation: Mean ± SD and comparison of groups using repeated measures ANOVA, paired t-test for pre- and post-intervention comparison.
2021 September 2021 November
Wexner Continence Assessment Scale Score - Fecal Incontinence Severity
Time Frame: September 2021 - November 2021
Description: Measures the severity of fecal incontinence. Minimum Value: 0 (Complete continence) Maximum Value: 20 (Complete incontinence) Higher Scores Indicate: Worse fecal incontinence Data Aggregation: Mean ± SD and comparison of groups using repeated measures ANOVA, paired t-test for pre- and post-intervention comparison.
September 2021 - November 2021
Fecal Incontinence Quality of Life Scale (FIQL) Score
Time Frame: September 2021 - November 2021
Description: Assesses the quality of life related to fecal incontinence. Minimum Value: 1 (Poor quality of life) Maximum Value: 5 (High quality of life) Higher Scores Indicate: Better quality of life Data Aggregation: Mean ± SD and comparison of groups using repeated measures ANOVA, paired t-test for pre- and post-intervention comparison
September 2021 - November 2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 15, 2021

Primary Completion (Actual)

November 5, 2021

Study Completion (Actual)

February 13, 2022

Study Registration Dates

First Submitted

February 8, 2025

First Submitted That Met QC Criteria

March 5, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 5, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 469
  • Hitit University (Other Identifier: Hitit University)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

There is a plan to make IPD and related data dictionaries available

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe